Tagged with BI

Switzerland Manufacturing – long sidelined as a relatively prosaic element of the global pharma supply chain – is back in the news. Investment in manufacturing facilities is skyrocketing as sponsors rush to meet soaring market demand, and the global industry is scrambling to align with the Trump administration’s threats and incentives…

Switzerland With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals – has undoubtedly intensified. Yet the industry continues to wield a super-size effect on the local economy, contributing up to a…

Switzerland For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact geography to achieve unprecedented levels of collaboration across key innovation hubs, rendering it possible to forge strong networks and partnerships…

France France is undergoing a quiet industrial renaissance in biomanufacturing, driven by a growing alignment between science, innovation, and policy. At the centre of this movement stands Laurent Lafferrère, CEO of France BioLead, who is leading efforts to structure the country’s ecosystem, foster collaboration, and attract sustainable investment. In this conversation,…

Denmark Drawn from Healthcare & Life Sciences Review Denmark 2025, this selection captures the major forces now reshaping one of Europe’s most dynamic life science hubs. From Denmark’s bid to double the sector’s economic weight by 2030, to its sweeping “Health Closer to You” reform, biotech surge, clinical-trials strategy, and evolving…

USA Duane Barnes, President of Sobi North America, outlines how the company has rapidly expanded its presence in the region to become a key player in rare diseases, growing its US business more than twenty-fold over the past decade. He discusses Sobi’s strong focus on haematology and immunology, the company’s upcoming…

Brazil Rogerio Frabetti, General Manager of Biogen Brazil discusses the organisation’s strategic transformation as it expands beyond its neuroscience heritage into immunology whilst maintaining leadership in rare diseases. He articulates Brazil’s elevation to a top-tier global market, outlines ambitious growth trajectories in Alzheimer’s disease and lupus, and addresses the complexities of…

LatAm Gianclaudio Broggi is CEO and chairman of Megalabs, one of Latin America’s largest biopharma organisations with operations spanning more than 20 countries and a workforce exceeding 9,000 employees. With over two decades at the company, he has been instrumental in its transformation from a 120 million USD enterprise into a…

USA New Jersey is home to one of the world’s most dynamic life sciences ecosystems, where global pharmaceutical leaders, cutting-edge biotechs, and a deep pool of talent converge. At the centre of this community stands BioNJ, the state’s trade association led by President and CEO Debbie Hart, who has spent more…

LatAm Roberto Alvarenga, VP at Biotronik’s Latin American operations, reflects on the company’s six decades of innovation and LatAm’s emergence as the firm’s fastest-growing region. He outlines a strategy focused on continuous innovation, digital health integration, and demonstrating health-economic value, while navigating the complex dynamics of public and private healthcare systems…

LatAm Vaccination remains the most powerful public health intervention ever devised, preventing an estimated 4.4 million deaths each year, according to the WHO. Yet with misinformation spreading faster than science, and routine immunisation disrupted by pandemic aftershocks, even long-protected regions are witnessing a resurgence in preventable diseases. In Latin America, where…

France At the helm of EG Labo (STADA Group), Tiago Bartolomeu is steering one of France’s leading accessible medicine players through a period of renewal and ambition. With a clear focus on expanding access through generics, biosimilars, and consumer health, he reflects on the company’s growth strategy, its role as a…